camlipixant

News

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning the programme.

News

MSD will have to return to the drawing board to chart a course for US approval of its chronic cough treatment gefapixant.

News

Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.